sr141716 has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ausseil, J; Briand-Mésange, F; Chap, H; Salles, J; Salles, JP; Trudel, S | 2 |
| Becker, KA; Carpinteiro, A; Cougoule, C; Gulbins, E; Hoertel, N; Kornhuber, J; Lemogne, C; Lenze, EJ; Limosin, F; Reiersen, AM; Sánchez-Rico, M; Seftel, D | 1 |
3 other study(ies) available for sr141716 and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?
Topics: Adipose Tissue; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Endocannabinoids; Humans; Obesity; Pandemics; Pneumonia, Viral; Prevalence; Respiration, Artificial; Rimonabant; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Can antidepressants unlock prescription of rimonabant in the fight against COVID-19?
Topics: Antidepressive Agents; COVID-19; Humans; Prescriptions; Rimonabant; SARS-CoV-2 | 2021 |
Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms.
Topics: Antidepressive Agents; Ceramides; COVID-19; Humans; Prescriptions; Rimonabant; SARS-CoV-2; Sphingomyelin Phosphodiesterase | 2021 |